COVID-19 First In Human Study to Evaluate Safety, Tolerability, and Pharmacokinetics of EIDD-2801 in Healthy Volunteers
Clinical trial NCT04392219 · COMPLETED
Trial details
- NCT number
- NCT04392219
- Sponsor
- Ridgeback Biotherapeutics, LP
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2020-04-10
- Primary completion
- 2020-08-11
- Enrollment
- 130
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.